• Intensity Therapeutics restarted dosing in its randomized Phase 2 INVINCIBLE-4 presurgical triple-negative breast cancer trial in Switzerland.
• Enrollment resumes following a pause to assess skin irritation; the amended regimen uses a lower drug-to-tumor ratio and a single INT230-6 injection.
• The study compares INT230-6 before standard neoadjuvant immuno-chemotherapy versus standard-of-care alone, with pathological complete response as the primary endpoint.
• Fourteen patients were treated before the pause; the INT230-6 arm showed a favorable trend toward fewer grade 3+ adverse events versus standard-of-care alone.
• The trial targets 47 additional patients in Switzerland and France.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Intensity Therapeutics Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607150745PR_NEWS_USPR_____NE04431) on July 15, 2026, and is solely responsible for the information contained therein.